Letter from the Editor

Dear Reader,

At EADV 2023, important innovations were reported on the treatment of inflammatory dermatoses. Whereas a decade ago targeted treatments were only introduced in psoriasis, targeted treatments for various inflammatory skin diseases are now innovating the options we have as dermatologists for highly effective long-term and safe control.

In atopic dermatitis, the aryl hydrocarbon receptor modulator tapinarof provides a new option for topical treatment, and anti-IL-13 treatments, JAK inhibitors,  and an OX40 ligand inhibitor are shown to be effective with a reasonable safety profile. Attention for the treatment of chronic hand eczema was raised and treatment with dupilumab proved to be effective in this frequently occurring disabling condition.

In psoriasis, attention was on spesolimab to prevent flares of generalised pustular psoriasis. Furthermore, the value of dual IL-17 blockade in psoriatic arthritis was shown. The superior drug survival of IL-23p19 inhibitors was shown in a registry study. The prevention of the development of psoriatic arthritis with IL-23 blockers was demonstrated. An innovation in the treatment of psoriasis was the high efficacy of a first in-class-oral IL-23 inhibitor.

In hidradenitis chronica suppurativa, sonelokumab (anti-IL-17A and F) proved to be effective. JAK inhibitors were shown to be effective in long-term studies. Also in alopecia arata and prurigo nodularis, JAK inhibitors provide new possibilities.

The management of inflammatory dermatoses is changing profoundly. What an outstanding future perspective for patients with inflammatory skin diseases.

Peter CM van de Kerkhof
Department of Dermatology Radboud UMC Nijmegen the Netherlands

Biography

Peter C.M. van de Kerkhof is emeritus Professor of Dermatology and immediate past chairman of the Department of Dermatology of Radboud University Nijmegen. He is currently the coordinating Medical Officer of the International Psoriasis Council and chair of the scientific advisory board of the Dutch burn association. He has been working for many years on the pathogenesis and treatment of psoriasis. He has published more than 700 publications in peer-reviewed journals and has given many presentations on invitation at international conferences. He has served as president of the ESDR, EDF, and the International Psoriasis Council, and was a board member of various international societies. Current interests are pathogenesis and development of biomarkers for psoriasis; real clinical practice research; and personalised medicine.

Conflict of Interest Statement:Consultancy services for: Celgene, Almirall, Amgen, Pfizer, Philips, AbbVie, Eli Lilly, Galderma, Novartis, Janssen Biotech, Janssen-Cilag, LEO Pharma,Sandoz, Mitsubishi Tanabe, Sandoz, Bristol Meyer Squibb, UCB, Dermavant.Speaker services for: Celgene, Almirall, Eli Lilly, Novartis, Jansen-Cilag, LEO Pharma, Sandoz, Bristol Meyer Squibb.



Posted on 28 November, 202322 April, 2024